Back to Search
Start Over
Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B.
- Source :
-
Clinics (Sao Paulo, Brazil) [Clinics (Sao Paulo)] 2024 Sep 26; Vol. 79, pp. 100493. Date of Electronic Publication: 2024 Sep 26 (Print Publication: 2024). - Publication Year :
- 2024
-
Abstract
- Objective: The role of Non-Alcoholic Fatty Liver Disease (NAFLD) on antiviral response in Chronic Hepatitis B (CHB) remains unclear. Previous studies mainly focus on the impact of the Non-Alcoholic Fatty Liver (NAFL) on antiviral efficacy, whereas the role of Non-Alcoholic Steatohepatitis (NASH) has not been highlighted. The authors aimed to investigate the association of NAFLD (NAFL and NASH), viral and histological characteristics with antiviral response.<br />Methods: The authors collected data of treatment-naïve CHB patients who underwent liver biopsy. All these patients received antiviral monotherapy and 48-week follow-up. The antiviral response was evaluated by Kaplan-Meier analysis. Cox regression analysis identified the variables associated with antiviral response.<br />Results: Overall, 120 treatment-naïve CHB patients were enrolled, with 49.2 % (59/120) of them were complicated by NAFLD. Male (Odd Ratio [OR = 4.222], 95 % Confidence Interval [95 % CI 1.620-11.003]) and overweight (OR = 8.709, 95 % CI 3.355-22.606) were independent predictors for concurrent NAFLD. After 48-week follow-up, the authors found that the overall antiviral response did not differ between CHB patients with and without concomitant NAFL/NASH (p > 0.05). High viral load (Hazard Ratio [HR = 0.522], 95 % CI 0.286-0.952), advanced fibrosis (HR = 2.426, 95 % CI 1.256-4.686), and moderate-to-severe interface hepatitis (HR = 2.541, 95 % CI 1.406-4.592) were significantly correlated with antiviral response after 8-week follow-up.<br />Conclusion: Neither NAFL nor NASH had an impact on antiviral therapy for CHB. It was low hepatitis B load, advanced fibrosis, and moderate-to-severe interface hepatitis that contributed to the virological response.<br />Competing Interests: Declaration of competing interest The authors declare no conflicts of interest.<br /> (Copyright © 2024 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.)
- Subjects :
- Humans
Male
Female
Adult
Biopsy
Middle Aged
Treatment Outcome
Viral Load
Kaplan-Meier Estimate
Retrospective Studies
Non-alcoholic Fatty Liver Disease pathology
Hepatitis B, Chronic drug therapy
Hepatitis B, Chronic complications
Hepatitis B, Chronic pathology
Antiviral Agents therapeutic use
Liver pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1980-5322
- Volume :
- 79
- Database :
- MEDLINE
- Journal :
- Clinics (Sao Paulo, Brazil)
- Publication Type :
- Academic Journal
- Accession number :
- 39332149
- Full Text :
- https://doi.org/10.1016/j.clinsp.2024.100493